Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | GPR6 | P46095 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667718 | 0.86 | GPR119 (0.50) | KMT2APDE4B | |
| SCHEMBL1668409 | 0.79 | KMT2A (0.34) | KMT2AHPGDERBB2EGFRPDE5A | |
| SCHEMBL1667653 | 0.79 | EPHX2 (0.43) | GPR6EPHX2 | |
| SCHEMBL1667476 | 0.78 | TBK1 (0.43) | KMT2APDE4B | |
| SCHEMBL1667831 | 0.76 | AAK1 (0.39) | HPGDERBB2EGFR | |
| SCHEMBL14862196 | 0.76 | PDE4B (0.47) | KMT2AEGFRPDE4BEPHX2ALDH1A1 | |
| SCHEMBL12448341 | 0.73 | GPR119 (0.50) | PDE4B | |
| SCHEMBL23121896 | 0.73 | PDE4B (0.55) | PDE4BALDH1A1 | |
| SCHEMBL15375545 | 0.73 | PDE4B (0.48) | GPR6PDE4B | |
| SCHEMBL1896056 | 0.73 | EPHX2 (0.45) | KMT2AEPHX2ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2488503-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | Myrexis, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | TBK1, NFKBIA, CHUK | KMT2A 3692/4885HPGD 1949/4885ERBB2 2284/4885 |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | TBK1, NFKBIA, IKBKB | KMT2A 1946/4885HPGD 2881/4885ERBB2 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.